Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dormio Tech, a division of Chad Therapeutics, has received 510(K) clearance from the FDA to market its proprietary FloChannel diagnostic system. Chad currently expects to begin shipping this new device and associated disposables by September 2008.
Subscribe to our email newsletter
Dormio Tech’s innovative FloChannel is said to be the only diagnostic device that independently monitors left and right nasal airflow.
This allows the system to detect and measure nasal cycling (the periodic alternation in nasal airflow resistance between the two nasal cavities), as well as oral airflow and snoring, and provides constant baseline airflow volumetric sleep scoring. The patented device connects easily to standard sleep lab systems.
Earl Yager, president and CEO of Chad Therapeutics, said: “With its patented features and unique capabilities, we believe FloChannel is a significant advance in the diagnosis of obstructive sleep apnea and other sleep disorders, and may become an invaluable tool in attended sleep laboratories.”